Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia

Pneumonia is an important cause of morbidity and mortality. COPD patients using inhaled corticosteroids (ICS) have an increased risk of pneumonia, but less is known about whether ICS treatment in asthma also i...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Research article Source Type: research

Related Links:

ConclusionThe use of ICS by the patients with CAP admitted to the hospital is not independently related with any radiological pattern, hospitalization duration and mortality. ICS usage may diminish fever response and may suppress the findings of crackles and/or bronchial sounds. This needs further confirmation.
Source: The Clinical Respiratory Journal - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conclusion: The determinants of suitability for HD-ICS prescription in primary care records are inconsistently recorded, difficult to identify and challenging to apply.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: General practice and primary care Source Type: research
Introduction: Inhaled corticosteroids (ICS) are effective in exacerbations prevention in patients with obstructive lung diseases. They were also related to increased risk of pneumonia. The aim of this study was to evaluate the effect on exacerbations of inhaled corticosteroids in a bronchiectasis population before a specialized study at a bronchiectasis clinic.Methods: Retrospective cohort study from Centro Hospitalar de Leiria (Portugal). Sample was divided into patients on previous ICS treatment (G1) and ICS naive group (G0). General demographics, microbiologic profile, lung function, comorbidities and exacerbation rate ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections Source Type: research
The objective was to determine the association of systemic CTS therapy with treatment failure and 30-day mortality in hospitalized patients with CAP. A retrospective cohort study was performed on patients who were admitted with CAP to pulmonology department of a University Hospital during the year of 2018. The primary exposure was the receipt of CTS and the primary outcome was 30-day mortality. A multivariable conditional logistic regression model was used to estimate the association between adjunct CTS and mortality, considering severity of pneumonia, immunosuppression status and chronic inflammatory lung disease. Of 117 ...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections Source Type: research
ConclusionsPotentially inappropriate ICS use is common among patients with and without airflow obstruction who are diagnosed with COPD. We identified patient comorbidities and patterns of healthcare utilization that increase the likelihood of ICS use that could be targeted for system-level de-implementation interventions.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
Mario Malerba1,2*, Valentina Foci1,2, Filippo Patrucco1,2, Patrizia Pochetti1,2, Matteo Nardin3, Corrado Pelaia4 and Alessandro Radaeli5 1Respiratory Medicine, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, Italy 2Respiratory Unit, Sant’Andrea Hospital, Vercelli, Italy 3Department of Medicine, Spedali Civili di Brescia, Brescia, Italy 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University “Magna Græcia” of Catanzaro, Catanzaro, Italy 5Department of Emergency, Spedali Civili di Brescia, Brescia, Italy Chronic obstructiv...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Sputum CXCL1 levels is a potentially better diagnostic marker for COPD than sputum CXCL8 levels, which is explained by that CXCL1 production in bronchial epithelial cells is less affected by therapeutic anti-inflammatory agents than CXCL8 production. PMID: 30676127 [PubMed - as supplied by publisher]
Source: Experimental Lung Research - Category: Respiratory Medicine Tags: Exp Lung Res Source Type: research
The efficacy, safety and positioning of inhaled corticosteroids (ICS) in the treatment of patients with chronic obstructive pulmonary disease (COPD) is much debated, since it can result in clear clinical benefits in some patients ("friend") but can be ineffective or even associated with undesired side effects, e.g. pneumonia, in others ("foe"). After critically reviewing the evidence for and against ICS treatment in patients with COPD, we propose that: 1) ICS should not be used as a single, stand-alone therapy in COPD; 2) patients most likely to benefit from the addition of ICS to long-acting bronchodil...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Reviews Source Type: research
CONCLUSION: Our case report supports the potential use of anti-IL-5 therapy for remission of patients with CEP with recurrent relapses. Whether, it would also be an effective initial therapy might also be an area that deserves future investigation. PMID: 30444149 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
Publication date: Available online 18 October 2018Source: The Lancet Respiratory MedicineAuthor(s): Samy Suissa, Sophie Dell'Aniello, Pierre ErnstSummaryBackgroundLong-acting β2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the recommended initial maintenance treatment for chronic obstructive pulmonary disease (COPD), with almost all LABAs dispensed in fixed combination with inhaled corticosteroids (LABA-ICS). We compared the effectiveness and safety of LABA-ICS versus LAMA treatment initiation as a function of blood eosinophilia, a potential biomarker of ICS effectiveness, in a real-world settin...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
More News: Asthma | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Pneumonia | Respiratory Medicine